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REVIEWThe Incidence of Sexual Dysfunction in Patients With Irritable Bowel
SyndromeJeanette Sørensen, MD,1,2,3 Birgitte Schantz Laursen, PhD,4,5 Asbjørn Mohr Drewes, DMSc,2,6 and
Anne Lund Krarup, PhD1,2,6ABSTRACTReceived Ap
1Centre of
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University,
5Clinical Nu
Sex Med 2Introduction: Several studies have suggested that patients with irritable bowel syndrome (IBS) frequently have
symptoms of sexual dysfunction.
Aim: The current study aims to map the current knowledge about the burden of sexual dysfunction in patients
with IBS.
Methods: A literature review was conducted on PubMed and EMBASE using the following search terms or
combinations thereof: irritable bowel syndrome; functional colonic disease; sexual function; sexual health; sexual
behavior; sexual dysfunction; dyspareunia; erectile dysfunction; quality of life; and questionnaire.
Main Outcome Measure: Sexual dysfunction.
Results: 1,273 texts were found, 331 duplicates were removed, and 844 texts were excluded because they did
not meet the inclusion criteria, leaving 98 full text articles. These were examined and it was found that 41
fulfilled the criteria. 4 questionnaires were found; Irritable Bowel Syndrome Quality of Life (IBS-QOL) ques-
tionnaire, the Irritable Bowel Syndrome e Quality of Life (IBSQOL) questionnaire, the Irritable Bowel
Syndrome-36 question (IBS-36) questionnaire, and the Arizona Sexual Experience Scale. Subscores for sexual
relations in IBS-QOL ranged from 37.7100 (11.9) for patients with IBS and 82.2100 (6.6) for controls. The
IBSQOL and IBS-36 subscores for sexual relations ranged from 49.790.5 (9) to 3.95.4 (0.8) with no healthy
controls for comparison. After interventions were implemented, there was an improvement in subscores
(the IBS-QOL mean changed to 10.5%, IBSQOL mean changed to 3.8%, and the IBS-36 mean changed to
40%). The study using Arizona Sexual Experience Scale showed that 51% of patients with IBS had sexual
dysfunction and also scored lower on the IBSQOL questionnaire.
Conclusion: The information about sexual dysfunction in patients with IBS is sparse and emerges primarily from
quality of life questionnaires. It seems as though patients with IBS have more sexual problems compared to
controls, but further investigation regarding the extent and type of sexual dysfunction is needed. Sørensen J,
Schantz Laursen B, Drewes AM, et al. The Incidence of Sexual Dysfunction in Patients With Irritable
Bowel Syndrome. Sex Med 2019;7:371e383.
Copyright  2019, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bloating, and changes in stool habits. It is further divided into
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372 Sørensen et almixed type. The recommendation for diagnosing IBS is to make
use of the Rome IV criteria.2
Quality of life (QOL) in patients with IBS has been shown to
be as low as the QOL measured in patients with diabetes mellitus
or end-stage renal disease.3 However, the disease does not only
have a negative impact on the general health-related QOL, but
also more specifically on sexual dysfunction. Hence, symptoms
of bloating, flatulence, soiling, and abdominal pain can impact
sexual life, and previous studies have shown significant sexual
dysfunction in patients suffering from IBS when compared to
healthy controls.46
In recent years, there has been more focus on sexual
dysfunction in patients suffering from inflammatory bowel dis-
ease.7,8 Studies have shown not only a higher occurrence of
sexual dysfunction, but also of sexual dysfunction independent of
disease severity.7 With a major overlap in symptoms between IBS
and inflammatory bowel disease, it could be speculated that
sexual dysfunction is also problematic for patients with IBS.9,10
Even though patients with IBS have symptoms that can lead
to sexual problems, no systematic reviews have targeted sexual
dysfunction in IBS. Knowledge in this field is of clinical
relevance to health care professionals in order to improve
QOL in this patient group. Therefore, we conducted a sys-
tematic review with the primary objective of synthesizing
existing knowledge regarding sexual dysfunction among pa-
tients suffering from IBS.
In general, sexuality and sexual functioning have been
demonstrated to be important for well-being and QOL. In a
Danish population study, 90% stated that their sexuality was
important, very important, or extremely important for their well-
being. Furthermore, sexuality and intimacy can provide means
for coping and developing survivorship skills for people living
with a life-threatening or chronic disease, as sexual and intimate
encounters can serve as a refuge in an otherwise chaotic and
turbulent situation.11METHODS
A systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines.12 Systematic searches in the PubMed and EMBASE
databases were undertaken inNovember 2018. The search strategy
used consisted of the following terms: “functional colonic disease,”
“irritable bowel syndrome,” and “quality of life,” both in Mesh
terms and text words. They were combined using AND in
conjunction with the terms “surveys and questionnaires” (both in
Mesh terms and text words) and then again combined using AND
in conjunction with the terms “sexual dysfunction” (Mesh),
“sexual behavior” (Mesh), “sexual health” (Mesh), “sexual” (text
word) OR “erectile dysfunction” (text word), and “dyspareunia”
(text word). We excluded the following terms: “sex offences”
(Mesh), “sexual abuse” (text words), “sexual violence” (text words),
and “cancer” (Mesh term and text word).Inclusion Criteria
The studies included in the review meet the following inclu-
sion criteria:
1. Peer reviewed articles. The articles showed a broad variety of
different types of studies, including observational and pro-
spective studies, but also intervention studies with some
randomized trials. A few articles were either validating a new
questionnaire or conducted a linguistic validation of an
already validated questionnaire.
2. Use of validated questionnaires with 1 or more questions
about sexual life. All information regarding sexual dysfunction
was accepted (dyspareunia, erectile dysfunction, lack/loss of
interest, etc.).
3. Questionnaires with values indicating the level of sexual
functioning.
4. Diagnosis of IBS using the Manning, Rome I, II, III, or IV
criteria.13
5. Publications in English.Exclusion Criteria
1. Other diseases or illnesses that could explain the sexual
dysfunction, including earlier sexual abuse or violence.
2. Age younger than 18 years and older than 90 years.
3. Studies with <10 participants.Data Collection and Analysis
The initial screening of the articles was performed by
reading the titles and abstracts. If IBS and QOL or any form
of sexual relations were mentioned, the articles were assessed
more thoroughly looking for specific data on sexual relations.
If none was identified, then the articles were excluded. All
articles that met the inclusion criteria went through a full text
analysis.RESULTS
Initially, 1,273 records relevant to the research terms were
found in the selected databases (see Figure 1). Of these, 331
articles were duplicated and, thus, removed, leaving 942 publi-
cations. After the first screening, 844 articles were excluded
because they did not meet the inclusion criteria. 98 potentially
eligible studies were identified. After examining the full texts, 41
articles were excluded. 7 articles did not use the Manning or
Rome criteria when diagnosing IBS, and another 2 analyzed
functional bowel diseases and not solely IBS. 11 articles did not
give precise information on the subscore for sexual relations in
the questionnaire. One article was excluded due to the inclusion
of children in the cohort. 5 studies only reported changes in the
subscore for sexual relations from baseline to after the interven-
tion. 2 studies were excluded as the same cohort was used in
other articles that had already been included. The majority (13)
of studies was excluded either due to the lack of informationSex Med 2019;7:371e383
Figure 1. Flow diagram for database search.
Sexual Dysfunction in Patients With IBS 373regarding the questionnaire in use or due to the use of a ques-
tionnaire that had not been validated. The final search resulted in
the inclusion of 57 studies.Questionnaires
In the final search we identified 4 questionnaires with infor-
mation on sexual relations among patients suffering from IBS.
Information primarily came from 2 questionnaires: the Irritable
Bowel Syndrome Quality of Life (IBS-QOL)14 questionnaire
and the Irritable Bowel Syndrome e Quality of Life (IBSQOL)
questionnaire.15 A description of these, in addition to the Irri-
table Bowel Syndrome-36 question (IBS-36)16 and the Arizona
Sexual Experience Scale (ASEX),17 is provided in Table 1. Only
1 study had sexual dysfunction as a measuring end point. All
other studies contained information on sexual relations from a
QOL questionnaire.IBS-QOL Questionnaire
Of the 57 included studies, 39 studies that make use of the
IBS-QOL questionnaire were included. The results of 35 of the
studies can be seen in Table 2.14,18e49 The questionnaire has 2
items regarding sexual function, with the following text:
“Because of my bowel problems, sexual activity is difficult for
me” and “My bowel problems reduce my sexual desire.” The
minimum score is 0, whereas the maximum score is 100, with a
higher score indicating higher QOL/less sexual problems. Sub-
scores for sexual relations ranged from 37.7100 (SD 11.9) for
patients with IBS. Only 5 studies reported information for
healthy controls with subscores ranging from 82.2100Sex Med 2019;7:371e383(SD 6.6). 14 papers described intervention studies with subscores
after intervention of 41.0100 (SD 12.2). Overall, there was an
improvement in subscores after an intervention (mean change of
10.5%).
In total, the subscores for sexual relations vary greatly from
one study to another, and only a few studies include healthy
controls. In 4 of 5 studies, there were higher scores among
healthy controls indicating less sexual problems, whereas the fifth
study found no difference in scores between healthy controls and
patients with IBS.
Four studies do not include specific data on sexual life but
only correlations with other symptoms, and they are, therefore,
not included in Table 2 but are described here. Ringel et al50
looked at QOL and found no difference between patients
complaining of bloating and nonbloating, with a sexual life score
of 73.4 and 79.8, respectively. Balboa et al51 show that patients
diagnosed with IBS and with upper digestive symptoms had a
lower score for sexual relations. The same could not be found for
the symptoms of heartburn or clinical functional dyspepsia. Jafari
et al52 looked at the correlation between the IBS-specific
symptom burden and sexual relations and found that a lower
IBS-QOL sexual relation score correlates with a higher IBS
symptom burden. Finally, Le Nevé et al53 found no significant
difference in the scores for sexual relations between patients with
IBS with low or high intensity gastrointestinal symptoms.IBSQOL Questionnaire
We found 17 studies using the IBSQOL questionnaire, with
15 studies providing specific scores for sexual relations (see
Table 1. Questionnaire overview
Instrument Author and year Description Score
IBS-QOL Patrick et al, 1998 Disease-specific HRQOL questionnaire
including 34 items, measuring 8
dimensions of health, including 2
questions regarding sexual relations
5-point Likert response scale ranging from 1
(“not at all”) to 5 (“extremely/a great
deal”). A summed total score is
transformed into 0100 range scale
(low score indicating low QOL)
IBSQOL Hahn et al, 1997 Disease-specific HRQOL questionnaire
including 30 items, measuring 9
dimensions of health, including 3
questions regarding sexual relations
5- or 6-graded scale. A summed total score
is transformed into a 0100 range scale
(low score indicating low QOL)
IBS-36 Groll et al, 2002 Disease-specific HRQOL questionnaire
including 36 items, measuring 8
dimensions of health, including 2
questions regarding sexual relations
7-point Likert scale where 0 ¼ “never” and
6 ¼ “always,” yielding a score between
0 and 216 (high score indicating low QOL)
ASEX McGahuey et al, 2000 Specific questionnaire for quantification
of sexual dysfunction in psychiatric
patients measuring 5 core elements
(drive, arousal, vaginal lubrication,
ability to reach orgasm, and
satisfaction from orgasm)
6-point Likert scale, ranging from 530,
with a higher score indicating a greater
level of sexual dysfunction. A total ASEX
score of >19, any 1 item with a score of
>5, or any 3 items with a score of >4
would indicate sexual dysfunction.
ASEX ¼ Arizona Sexual Experience Scale; HRQOL ¼ health related quality of life; IBS-36 ¼ Irritable Bowel Syndrome-36 question; IBS-QOL ¼ Irritable
Bowel Syndrome Quality of Life questionnaire; IBSQOL ¼ Irritable Bowel Syndrome e Quality of Life questionnaire.
374 Sørensen et alTable 3).15,54e66 The questionnaire contains 3 items regarding
sexual function, asking about interference related to sexual ac-
tivity, avoidance of sexual activity, and lowered satisfaction levels.
The minimum score is 0 and the maximum is 100, with a higher
score indicating higher QOL/less sexual problems. Subscores for
sexual relations ranged from 49.790.5 (SD 9.5). Only 1 study
included controls exhibiting other gastrointestinal diseases,15 and
indicates higher subscores for sexual relations than patients with
IBS corresponding to better QOL in the sexual domain. None of
the studies included healthy controls and it is, therefore, not
possible to conclude whether or not patients with IBS have more
or less sexual problems than healthy controls.
7 studies had interventions with subscores ranging from
55.282 (SD 8.6). 11 of the 14 articles show improvement in
subscores after an intervention, corresponding to an increase in
QOL in the sexual domain. 2 studies report no change after an
intervention and 1 study shows a lower score after intervention.
2 studies do not include specific data on sexual relations, but
look at correlations to other factors. Böhn et al67 looks at the
correlation between avoiding specific food items and QOL, and
found no significant correlation between sexual relations and
food items reported to result in gastrointestinal symptoms. One
study only includes data on sexual relations in correlation with
low or high frequency symptoms. In general, it was found that a
low intensity frequency pattern gave a higher sexual relation score
than a high intensity frequency pattern.68IBS-36 and ASEX
Only 1 study uses the QOL questionnaire IBS-36
(see Table 4).69 The IBS-36 questionnaire contains 2 itemsthat read: “Did your bowel condition interfere with having sexual
relations?” and “Did your bowel symptoms interfere with your
desire to have sexual relations with your partner?” The minimum
score is 0 and the maximum score is 12, with higher scores
indicating more sexual problems. The study does not make use
of healthy controls for comparison. There was an improvement
in sexual relations subscores and thereby an increase in QOL in
the sexual domain after the intervention for all 3 groups in the
study (with a mean change of 40%).
Eugenio et al62 conducted the only study addressing sexual
dysfunction more specifically through the use of ASEX. The aim
was to compare demographics and clinical factors in women with
IBS with or without sexual dysfunction using both ASEX and
IBSQOL. The results are reproduced in Table 5. The cohort was
divided into 2 groups depending on whether or not sexual
dysfunction was reported according to the ASEX questionnaire.
51% of the cohort with IBS had sexual dysfunction. They also
show that patients with sexual dysfunction have significantly
lower sexual relations scores in the IBSQOL, indicating that IBS
negatively impacts sexual relations. In order to evaluate the
quality of the studies we used Jadad Score. The Jadad Scores for
the included studies are shown in Tables 6e9.DISCUSSION
In this systematic review, a search was done through PubMed
and EMBASE for information regarding sexual dysfunction in
patients with IBS. We chose these 2 databases as they include
research papers from all medical and psychological disciplines. Of
the 57 papers included, 56 measured health-related QOL andSex Med 2019;7:371e383
Table 2. IBS-QOL questionnaire
Study
No of
patients Female % Female
Age
(mean)
Healthy
controls
% with
IBS-C
% with
IBS-D/Mixed
type
Score before
intervention
Score before
intervention
(healthy controls)
Du n of
int ntion
Intervention
type
Score after
intervention
(patients)
Abbasnezhad, 2016 44 28 63.6 37.5 34.1 65.9 69.4 6 m Vitamin D 85.1
41 29 70.7 38.3 34.1 65.9 68.4 6 m Placebo 79.5
Abel, 2018 809 527 65.1 46.4 64.0 26 Placebo 78.0
808 537 66.5 44.8 64.0 26 Elux 75 78.0
806 538 66.7 45.0 64.0 26 Elux100 78.0
Ahmed, 2011 40 32 80.0 77.0 37.5 62.5 67.5 93.7
Begtrup, 2013 67 51 76.1 31.6 20.9 79.1 78.2 6 m Probiotics 82.4
64 46 71.9 29.4 17.2 82.8 72.5 6 m Placebo 79.6
Boltin, 2015 15 11 73.3 38.9 20.0 80.0 73.2 GAI 73.2
19 15 78.9 53.1 36.8 63.2 75.0 8 w Control 82.9
Canon, 2017 240 22.6 84.5
0 90.4
Cash, 2017 2579 1759 68.2 46.4 65.2 Rifaximin open label
328 222 67.7 47.9 69.7 Rifaximin dbl blind
308 219 71.1 45.6 69.4 Placebo
Cha, 2012 25 13 52.0 37.9 88.0 8 w Probiotics 93.5
25 11 44.0 40.3 92.4 8 w Placebo 97.0
Cho, 2011 124 61 49.2 45.8 91.0 24.2 75.8 89.3
Choi, 2011 45 17 37.8 40.2 22.2 77.8 86.6 4 w S.boulardii 92.9
45 20 44.4 40.6 13.3 86.7 85.0 4 w Placebo 86.9
De Gucht, 2015 123 108 87.8 32.4 70.3
Drisko, 2006 20 15 75.0 73.1 3-4 Diet 79.6
Drossman, 2009 1966 1632 83.0 40.4 60.2
El-Salhy, 2010 143 136 95.1 32 32.9 67.1 76.0 3 m Info, diet, excercise,
probiotika
87.0
Frändemark, 2018 370 307 83.0 35.0
(median)
9.7 90.3 57.8
Gholamrezaei, 2011 141 115 81.6 30.8 32.6 67.4 62.1
Graham, 2010 113 113 100.0 48.5 224.0 64.8 82.8
Huang, 2007 61 36 59.0 33.4 70.0 37.7 99.3 4 w 41.0
Jang, 2014 39 39 100.0 21.9 53.8 46.2 98.1 24 Cognitive therapy 100.0
37 37 100.0 21.2 45.9 54.1 99.3 24 Control 98.7
Kang, 2011 89 16 18.0 28.1 12.4 87.6 92.4 9 w Lifestyle modification 95.9
Kim, 2010 81 81 100.0 46.2 86.9 4 w Tegaserod 87.5
Kopczynska, 2018 87 69 79.3 39.2 56.0 41.2 58.8 76.4 99.8
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Table 2. Continued
Study
No of
patients Female % Female
Age
(mean)
Healthy
controls
% with
IBS-C
% with
IBS-D/Mixed
type
Score before
intervention
Score before
intervention
(healthy controls)
D ration of
in rvention
Intervention
type
Score after
intervention
(patients)
Lauche, 2015 44 40 90.9 53.9 27.1 72.9 76.1 3 k CarO 77.1
41 76.5 3 k OlivH 76.3
41 80.2 3 k OlivC 85.8
Lee, 2008 159 144 63.6 39.4 69.0
261 228 63.6 40.7 73.4
Park, 2006 103 74 71.8 38.3 46.0 54.0 87.1
Park, 2009 664 367 55.3 43.0 25.3 74.7 86.7
Patrick, 1998 155 138 89.0 39.0 73.5
Remes-Troche, 2015 47 44 93.6 42.0 49.0 53.0 47.0 85.0 97.0
Schmulson, 2007 63 63 100.0 42.6 51.0 49.0 76.6
63 63 100.0 42.5 51.0 49.0 71.8
Sherwin, 2016 101 79 78.2 42.0 66.8
Singh, 2015 54 47 45.4 100 73.9
56 51 42.8 100 74.6
121 85 41.3 100 68.8
Tana, 2009 26 13 50.0 21.9 26.0 42.3 57.7 100.0 100.0
ten Berg, 2006 169 105 62.1 50.2 83.0
Voci, 2009 144 144 100.0 32.5 7.0 93.0 52.4
Zhu, 2015 227 44.68 83.1
94 82.3
133 0 83.7
Some studies have several groups included in the study; each are listed in the table above.
CarO ¼ caraway oil poultice; GAI ¼ guided affective imagery; IBS-QOL ¼ Irritable Bowel Syndrome Quality of Life questionnaire; OlivC ¼ non-hea d olive oil poultice; OlivH ¼ hot olive oil poultice; S.
boulardii ¼ Saccharomyces boulardii.
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Table 3. IBSQOL Questionnaire
Study
No of
patients Female % Female
Age
(mean)
Healthy
controls
% with
IBS-C
% with
IBS-D/Mixed
type
Score before
intervention
(patients)
Score before
intervention
(controls)
Duration of
intervention Intervention type
Score after
intervention
Amouretti, 2006 253 192 75.9 47.6 79.5
61 0.0 48.5 90.5
Bjorkman, 2015 405 405 72.7 43.1 58.0
152 0 0.0 40.1 69.0
Chassany, 1998 227 65.0
Cremonini, 2012 705 177 100.0 45.9 51.8 2 wk Alosetron 0.5 mg
175 100.0 46.6 52.7 2 wk Alosetron 1.0 mg once
a day
177 100.0 47.7 55.9 2 wk Alosetron 1.0 mg
twice a day
176 100.0 46.6 53.9 2 wk Placebo
Euenio, 2012 86 86 100.0 38.7 69.7 Non-sexual
dysfunction
89 89 100.0 46.2 69.7 Sexual dysfunction
Hahn, 1997 248 37.0 64.9 90,0
Johannesson, 2015 39 32 82.1 45.0 28.2 71.8 60.0 12 wk Physical activity 60
Lindfors, 2012 45 35 77.8 40 15.6 84.4 49.7 1 y Hypnotherapy 61.3
45 36 80.0 41 15.6 84.4 54.7 3 mo Control 55.2
Lindfors, 2013 83 65 78.3 42.0 15.7 84.3 55.1 12 wk Hypnotherapy 60.9
Ringstrøm, 2007 218 151 69.3 42.0 20.2 79.8 74.0
Ringstrøm, 2009 72 117 162.5 38 21.7 78.3 58.0 6 mo IBS-school 75
71 117 164.8 38 21.7 78.3 58.0 6 mo Guidebook 67
Ringstrøm, 2012 40 33 82.5 36.0 0.0 27.5 72.5 50.0 12 mo Long group
IBS-School
67
40 37 92.5 38.0 0.0 17.5 82.5 58.0 12 mo Short group IBS
school
54
Simrén, 2009 37 37 100.0 42 13.0 87.0 67.0 Active 75
37 37 100.0 44 16.0 84.0 67.0 Control 67
Watson, 2001 317 45.3 64.0 12 wk Placebo 69
309 46.5 70.0 12 wk Alo001 82
323 45.6 63.0 12 wk Placebo 68
324 46.5 69.0 12 wk Alo002 80
Williams, 2006 98 0 0.0 75.7 Healthcare seekers
239 239 100.0 72.2 Healthcare seekers
Alo001 ¼ alosetron hydrochloride (U.S. clinical trial study S3BA001); Alo002 ¼ alosetron hydrochloride (U.S. clinical trial study S3BA3002); IBS ¼ irritable bowel syndrome; IBSQOL ¼ Irritable Bowel
Syndrome e Quality of Life questionnaire.
S
ex
M
ed
20
19
;7:371e
38
3
S
exualD
ysfunction
in
Patients
W
ith
IB
S
377
Table 5. ASEX questionnaire
Study
No of
patients Female % Female
Age
(mean)
Healthy
controls % with IBS-C
% with IBS-D/Mixed
type
Score before
intervention
IBSQOL - subscore
sexual relations
ASEX sexual
dysfunction
Eugenio, 2012 86 86 100 38.7 23 77 11.9 69.7 No dysfunction
89 89 100 46.2 28 72 20.6 69.7 Dysfunction
ASEX ¼ Arizona Sexual Experience Scale.
Table 4. IBS-36 questionnaire
Study
No of
patients Female % Female Age (mean)
Healthy
controls % with IBS-C
% with
IBS-D/Mixed
type
Score before
intervention
Score before
intervention
(healthy controls)
Duration of
intervention
Intervention
type
Score after
intervention
(patients)
Wilson, 2013 15 10 66.7 49.1 5.4 6 wk SBI 10 g 3.2
16 8 50.0 44.9 4.3 6 wk SBI 5 g 2.9
14 10 71.4 47.8 3.9 6 wk Placebo 2.0
IBS-36 ¼ Irritable Bowel Syndrome-36 question; SBI ¼ serum-derived bovine immunoglobulin/protein isolate.
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Table 6. Jadad score for studies using IBS-QOL.
Jadad score Randomization Double blind Withdrawals/dropout Total points
Abbasnezhad, 2016 2 2 1 5
Abel, 2018 1 2 0 3
Ahmed, 2011 0 0 0 0
Begtrup, 2013 2 2 1 5
Boltin, 2015 2 0 0 2
Canon, 2017 0 0 1 1
Cash, 2017 2 2 0 4
Cha, 2012 2 2 1 5
Cho, 2011 0 0 1 1
Choi, 2011 2 2 1 5
De Gucht, 2015 0 0 0 0
Drisko, 2006 0 0 1 1
Drossman, 2009 0 0 0 0
El-Salhy, 2010 0 0 1 1
Frändemark, 2018 0 0 1 1
Gholamrezaei, 2011 0 0 0 0
Graham, 2010 0 0 1 1
Huang, 2007 0 0 1 1
Jang, 2014 2 0 1 3
Kang, 2011 0 0 1 1
Kim, 2010 0 0 0 0
Kopczynska, 2018 0 0 0 0
Lauche, 2015 2 0 1 3
Lee, 2008 0 0 0 0
Park, 2006 0 0 0 0
Park, 2009 0 0 1 1
Patrick, 1998 0 0 0 0
Remes-Troche, 2015 0 0 0 0
Schmulson, 2007 0 0 0 0
Sherwin, 2016 0 0 0 0
Singh, 2015 0 0 0 0
Tana, 2009 0 0 0 0
ten Berg, 2006 0 0 0 0
Voci, 2009 0 0 0 0
Zhu, 2015 0 0 0 0
Ref: Jadad et al, 1996.
Randomization: 1. Was the study described as randomized? Double blinding: Was the study described as double blind? Withdrawals/dropouts? Was there a
description of withdrawals and dropouts? Yes ¼ 1 point, No ¼ 0 points. Additional points for randomization described and appropriate, and double blinding
described and appropriate. Deduction of points if randomization described but inappropriate or double blinding described but inappropriate.
IBS-QOL ¼ Irritable Bowel Syndrome Quality of Life questionnaire.
Sexual Dysfunction in Patients With IBS 379not sexual relations specifically. Furthermore, most studies con-
tained a QOL assessment only as a secondary end point. In all 56
studies, sexual dysfunction was measured by only 1 item in a
QOL questionnaire.
We engaged the literature with 2 questions in mind: which
questionnaires are used to describe sexual functioning in patients
with IBS, and what information do these questionnaires provide
about sexual dysfunction and if it is more or less prevalent in
patients suffering from IBS compared to others.
The use of QOL questionnaires gives a broad idea of the general
well-being of patients with IBS, however, this does not address what
the problem is, nor whether the patient’s psychological state has anySex Med 2019;7:371e383influence on the bowel symptoms. It has traditionally been assumed
that a low score for sexual relations in a questionnaire equates sexual
dysfunction from a clinical perspective. There is no further
description of the type and extent of sexual dysfunction and no
consideration of which disease or illness the patient may have. In
our systematic review, we found that for the IBS-QOL question-
naire only 5 studies had comparable information on healthy con-
trols. The IBS-QOL questionnaire only had information including
controls from 1 questionnaire, and these controls were not healthy
but were patients with other gastrointestinal disorders. The 1 study
making use of the IBS-36 also did not include healthy controls. The
review demonstrates that information relating to sexual dysfunction
Table 7. Jadad score for studies using IBSQOL
Jadad score Randomization Double blind Withdrawals/dropout Total points
Amouretti, 2006 0 0 0 0
Bjorkman, 2015 0 0 0 0
Chassany, 1998 0 0 0 0
Cremonini, 2012 2 2 1 5
Eugenio, 2012 2 0 1 3
Hahn, 1997 0 0 0 0
Johannesson, 2015 2 0 1 3
Lindfors, 2012 2 0 1 3
Lindfors, 2013 2 0 1 3
Ringstrøm, 2007 0 0 0 0
Ringstrøm, 2009 2 0 1 3
Ringstrøm, 2012 2 0 1 3
Simrén, 2009 2 2 1 5
Watson, 2001 0 2 0 2
Williams, 2006 0 0 0 0
IBSQOL ¼ Irritable Bowel Syndrome e Quality of Life questionnaire.
380 Sørensen et alin patients with IBS is very sparse and, in most of the published
studies, limited to 1 question. Information on the type of sexual
dysfunction and the relation to gastrointestinal symptoms is lacking.
Nonetheless, it does seem that there could be a lower score indi-
cating more sexual problems for patients with IBS than for healthy
controls, when looking solely at the IBS-QOL studies. More
studies, however, are required to confirm this.
It is well known that patients with IBS have low QOL, and it
is often referred to as also having sexual dysfunction. The evi-
dence supporting the latter comes primarily from older
studies.4,6,70 However, these studies were excluded due to a lack
of validated questionnaires or because patients did not fulfil the
established Manning or Rome criteria. Whether or not low QOL
in patients with IBS results in sexual dysfunction remains to be
examined in studies using validated questionnaires.
The present study found the use of only 4 questionnaires,
although other questionnaires are also used also to measure QOL
and include questions on sexual relations. They are the Patient
Health Questionnaire 15, the World Health Organization
Quality of Life BREF, and the Modified Manchester Health
Questionnaire. Studies using these other questionnaires were
excluded due to the lack of specific data on questions regarding
sexual relations. For these other QOL questionnaires we expect
the same challenges to emerge, as they are constructed for a broad
view on health-related QOL and do not specifically focus on
sexual relations.Table 8. Study using IBS-36 questionnaire
Jadad score Randomization
Double
blind
Withdrawals/
dropout
Total
points
Wilson, 2013 2 2 1 5
IBS-36 ¼ Irritable Bowel Syndrome-36 question.The question, however, is whether or not the use of QOL
questionnaires can provide exact knowledge about sexual
dysfunction by asking 1 question about sexual relations.
Bearing in mind that QOL questionnaires are designed to give
an overview of many aspects of life and are not specifically
designed to give information on sexual life, one can question if
the results answers our question “is sexual dysfunction more
common in patients suffering from IBS than healthy controls?”
The only study that used both IBSQOL and the specific sexual
relations questionnaire, ASEX,62 detected a difference in scores
for patients with IBS with and without sexual dysfunction, as
defined by the ASEX questionnaire. In other words, the pa-
tients with sexual dysfunction scored lower in their sexual re-
lations subscore than those who do not have sexual
dysfunction. This might support the assumption that a low
score in the IBSQOL questionnaire indicates sexual
dysfunction.
A history of sexual abuse among patients suffering from IBS is
more common than in healthy controls or patients suffering from
other functional gastrointestinal syndromes.71 We, therefore,
excluded studies on this group as it could be a confounder.
Furthermore, none of the included studies contained informa-
tion regarding the patients’ sexual orientations. However, sexu-
ality is a human phenomenon and is independent of gender or
sexual orientation.11 The questionnaires also provide only
limited information regarding different sexual domains (desire,Table 9. study using ASEX questionnaire
Jadad score Randomization
Double
blind
Withdrawals/
dropout
Total
points
Eugenio, 2012 2 0 1 3
ASEX ¼ Arizona Sexual Experience Scale.
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Sexual Dysfunction in Patients With IBS 381arousal, lubrication, orgasmic function, satisfaction, and pain)
and only covers 1, 2, or 3 items.Limitations to the Study
All but 1 of the studies was not intended to solely evaluate
sexual dysfunction in patients suffering from IBS. The studies
have a great variety in design; some being intervention studies
other descriptive, etc. Even though designs for some of the
studies may seem similar there are still differences in intervention
type, duration of intervention, and control groups. With the use
of the Jadad score, we evaluated the quality of the studies
(Tables 6, 7, 8, and 9) and found that a majority of the studies
using the IBS-QOL questionnaire had a score of 0 or 1 (score
05, 0 being the lowest score). For the IBSQOL questionnaire
the score overall were higher but still only 2 studies scored 5.CONCLUSIONS
Information relating to sexual dysfunction in patients with
IBS is sparse in the existing literature and emerges primarily
from QOL questionnaires where questions regarding sexual
dysfunctions are only 1 of many subscores. Such QOL ques-
tionnaires, which dedicate just 1 question to the description of
sexual function, are not sufficient to describe the complexity of
human sexuality. Nonetheless, from the available research it
seems that patients with IBS may have more sexual problems
compared to healthy controls. The type and extent of the
sexual dysfunction remains unknown and further studies
focusing specifically on the patients’ sexuality are needed in
order to provide further insight and sufficient treatment for
patients with IBS.
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